Head and neck squamous cell carcinoma (HNSCC) is the 8th leading cause of cancer death worldwide, largely due to a rising epidemic of oropharynx cancer associated with the human papillomavirus (HPV). Head and neck cancer is a complex disease that historically has been associated with high recurrence rates and poor long-term outcomes, highlighting the critical need for new treatment options. Despite advances in surgery and chemoradiation therapy, there has been little improvement in survival rates. The management of advanced HNSCC consists of multiple-modality therapy with surgery, radiation, and chemotherapy. Palliative radiation therapy is beneficial for treating symptomatic metastatic sites. Selective drugs have been developed that target either the extracellular ligand-binding region of the EGFR (including a number of monoclonal antibodies, immunotoxins, and ligand-binding cytotoxic agents) or the intracellular tyrosine kinase region (including various small-molecule inhibitors). Targeted therapies such as cetuximab, panitumumab, zalutumumab, nimotuzumab, erlotinib, gefitinib and lapatinib against the epidermal growth factor receptor (EGFR) are the most promising molecular therapeutics for head and neck squamous cell carcinoma. Drugs commonly used as single agents in the treatment include docetaxel, paclitaxel, cetuximab, capecitabine, pemetrexed, and methotrexate. Two checkpoint inhibitors or programmed cell death protein 1 (PD1) inhibitors, Pembrolizumab (Keytruda), manufactured by Merck & Co. and Nivolumab (Opdivo), manufactured by Bristol-Myers Squibb received FDA accelerated approval in 2016. New therapies include mTOR inhibitors, anti-angiogenic agents, and IGF1R inhibitors.
The global head and neck squamous cell carcinoma drugs market segmentation is based on drug class – cytotoxic agents, epidermal growth factor receptor (EGFR) inhibitors, programmed cell death protein 1 (PD1) inhibitors, PD1 ligand 1 (PDL1) inhibitors, cytotoxic T lymphocyte antigen 4 (CTLA4) inhibitors.
The global head and neck squamous cell carcinoma drugs market research report provides market size (Revenue US$ Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global head and neck squamous cell carcinoma drugs market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Latin America (Brazil, Mexico, Rest of LA), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global head and neck squamous cell carcinoma drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global head and neck squamous cell carcinoma drugs market and profiled in this report include Advaxis, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, CEL-SCI, Five Prime Therapeutics, Incyte, IRX Therapeutics, MacroGenics, Merck KGaA, Novartis, Ono Pharmaceuticals (BMS), and Pfizer.